
Advertise on podcast: RetinUp Podcast
Rating
4.3from
This podcast has
40 episodes
Language
EnglishPublisher
RetinUp Podcast, LLCExplicit
No
Date created
2025/10/28
Latest episode
2026/11/10
Average duration
25 min.
Release period
7 days
Description
RetinUp is a podcast exploring the latest in retina science and ophthalmology. Hosted by John Kitchens, MD, and Scott Krzywonos, each episode features expert insights, research breakthroughs, and practical discussions designed for ophthalmologists, retina specialists, and vision science researchers.
Unlock RetinUp Podcast podcast Email contact info,
Listeners & Audience details
Email contact information
Direct podcast contact details

Listeners
Audience numbers & engagement insights

Audience details
Podcast Insights

Podcast episodes
Check latest episodes from RetinUp Podcast podcast
Breaking News: Imvionix Acquires Beovu in the US and Canada
2026/11/10
Imvionix has acquired the exclusive US and Canadian commercial rights to Beovu (brolucizumab) from Novartis. The deal is the first strategic transaction for the new company, led by Rick Eiswirth, former CEO of Alimera Sciences. John Kitchens, MD, and Scott Krzywonos react to the news, explain why Beovu still matters to some patients despite its limited US use, and ask what a dedicated owner could change. They also look at which other neglected retina products could be next.
Hosts: John Kitchens, MD, Scott Krzywonos
Topics Covered
The Deal
Imvionix announced it has acquired exclusive commercial rights to Beovu in the US and Canada from Novartis. Scott reads the press release language about an organization with deep relationships in the retina community being best positioned to “expand the reach of such therapies,” and takes the plural as a sign that more acquisitions may follow.
John knows Rick Eiswirth, who has spent about 20 years in the retina space, and likes the leadership. His hope is that Imvionix helps maintain access to niche products that major manufacturers no longer want to support, as Novartis selling Beovu suggests.
Why Access Matters
Beovu is rarely used in the US, largely because of the retinal vasculitis reports that followed its launch. John still values having it available, because it works for some patients. Scott points to Harrow’s acquisition of Triesence from Alcon as a model: the product was unavailable for a couple of years and is now easy to get.
The Molecule
Brolucizumab was the first second-generation anti-VEGF agent, alongside Vabysmo and Eylea HD. John says the HAWK and HARRIER studies showed a strong drying effect and durability, and that many retina specialists consider it the strongest drying agent.
Scott noticed at this year’s ASRS Preferences and Trends survey posters that Beovu use registered in Asia-Pacific for exudative disease but not in other regions. John, after talks in Australia and Taiwan about six months ago, says physicians there still rely on it for difficult idiopathic polypoidal choroidal vasculopathy. He adds, anecdotally, that they report less retinal vasculitis than first described. Scott wonders whether closer monitoring has reduced the consequences of those events.
What Imvionix Could Do
John calls Beovu an unsupported drug in the US, with no sales force behind it. Scott suggests the label “unsupported” over “orphan,” since orphan implies an orphan indication. He expects support for access and samples, and further research on the inflammatory events. Scott adds patient selection as a likely topic. John doubts that will be enough to raise US share now that faricimab and aflibercept 8 mg are available, but welcomes a company with an identifiable face behind the drug.
Next Candidates
John’s list of neglected products: photodynamic therapy, Retisert (a surgical implant that treats uveitis), and products that keep going on back order, including ICG and fluorescein.
Key Takeaways
Imvionix is built around retina relationships, and the hosts read its press release as a sign of more deals.
Beovu is used sparingly in the US but still helps some patients, especially in Asia-Pacific for polypoidal disease.
A company with a real commercial team behind Beovu could mean access, samples, and new data on inflammation and patient selection.
Products that are niche, withdrawn, or repeatedly back ordered are the next likely acquisition targets.
Credits
Production & Marketing: Laura Brown | Business Operations: Liz Hogan
🎧 Listen at RetinUp.com | Apple Podcasts | Spotify | YouTube
Business of Retina After the Midterms with Tom Stone, MD | Ehsan Rahimy, MD, on the PRIMA Implant
2026/11/05
Recorded the after the 2026 midterms, John Kitchens, MD, and Scott Krzywonos ask Thomas Stone, MD, what a shift in Congress could mean for retina practices: drug pricing, surgical reimbursement, Medicare expansion, the GLOBE Project, and a biosimilar market that is already changing practice economics.
The Vitreoretinal View features Ehsan Rahimy, MD, on the PRIMA subretinal photovoltaic implant (Science Corporation) for advanced geographic atrophy. He covers how the device works, the surgery, rehabilitation, three-year safety data from the PRIMAvera trial, how PRIMA differs from Argus II, and why FDA action could arrive sooner than many US retina specialists expect.
Hosts: John Kitchens, MD, Scott Krzywonos
Topics Covered
Business of Retina After the Midterms (Thomas Stone, MD)
Scott floats a thesis that 2026 echoes 2006, and that the healthcare reform of 2008 could occur again in 2028 if a Democrat takes the White House. John and Tom expect little legislative change before 2029 because of the presidential veto, but see the results giving Democrats a platform on healthcare.
Tom’s watch list: continued pressure on surgical reimbursement. Expansion of Inflation Reduction Act drug negotiation, with 20 more drugs selected in 2027 and talk of 50. Proposals to shorten the biologic timeline from 11 years to 5. Medicare expansion options, including a public option and a lower eligibility age.
GLOBE Project: Tom says it is not high on his radar. John expects the impact to fall on manufacturers and distributors more than on practice drug reimbursement.
2027 practice economics: biosimilars have created a market practices must respond to. Tom points to Lucentis, where ASP erosion left practices underwater.
Patient assistance: after two years of uncertainty in Medicare Advantage copay foundation funding, a fund covering several hundred of Tom’s patients sunset in October. Practices need to be ready to enroll patients the moment funds open.
Meetings: Tom previews the Cencora Vision Exchange in Orlando and the March 2027 Business of Retina meeting, which will feature a keynote speaker from Microsoft covering AI, as well as sessions on staffing and recruitment.
Vitreoretinal View: PRIMA Implant (Ehsan Rahimy, MD)
The device: a 2 x 2 mm, 30 µm photovoltaic chip with 378 pixels, placed subretinally with no battery or cables. Glasses with a camera and pocket processor project near infrared light onto the chip, which stimulates bipolar cells. Patients combine form vision with native peripheral vision.
The surgery: pars plana vitrectomy, subretinal bleb, roughly 3 mm retinotomy, a pick to separate adherent retina at the GA border, and perfluorocarbon to stabilize the chip on insertion. Tamponade is required (70% gas, 30% oil in PRIMAvera). No retinotomy laser.
Rehabilitation: more than 60 hours of structured training. Dr. Rahimy expects US centers of excellence.
Outcomes: ~25 ETDRS letters gained at 12 months and about 30 at 36 months. 84% of compliant participants reported reading letters and words, and 52% used the device for complex tasks such as playing cards. Entry acuity was no better than 20/320 in the study eye and 20/200 in the fellow eye.
Safety: 38 patients, 17 sites, five countries. 27 completed 36 months. Seven died of all-cause mortality, none attributed to the device or procedure. 29 serious adverse events, 83% within 6 months. Natural vision was preserved. Placement in maculas 50 µm or thinner is best avoided.
Compared to Argus II: Argus is epiretinal and RF powered, with about 60 electrodes and extraocular cables. PRIMA is subretinal, uses 378 pixels at 100 µm pitch, and did not migrate beyond GA borders.
FDA: two Humanitarian Use Device designations, for advanced GA and Stargardt disease. Dr. Rahimy says Science Corporation has filed for a Humanitarian Device Exemption, with a decision possible by year end or early 2027. Candidates need pure GA with intact inner retina, so concurrent glaucoma would exclude a patient.
Key Takeaways
The hosts see little chance of healthcare legislation before 2029, but drug pricing and reimbursement debates could reach retina sooner.
The market, more than politics, is driving 2027 practice economics: biosimilars, ASP erosion, and shifting patient assistance funds.
PRIMAvera showed functional central vision gains in end-stage GA with a manageable safety profile, and a US decision could come within months.
Candidates are narrow: advanced GA, intact inner retina, and capacity for extensive rehabilitation.
Sponsors
This episode of RetinUp is supported by Genentech, Astellas, and Alcon.
Credits
Production & Marketing: Laura Brown | Business Operations: Liz Hogan
🎧 Listen at RetinUp.com | Apple Podcasts | Spotify | YouTube
Big Pharma’s Retina Bets | Don D’Amico, MD, on BRUNELLO | RetinUp Turns One
2026/10/29
RetinUp turns one year old. Before the birthday reflections, John Kitchens, MD, and Scott Krzywonos take stock of what the past eighteen months of retina acquisitions actually mean: Merck’s purchase of EyeBio for up to $3 billion, Eli Lilly’s acquisition of Adverum Biotechnologies for up to $262 million, Biogen’s acquisition of Apellis for $5.6 billion, and AbbVie’s licensing partnership with RegenxBio worth up to $1.75 billion. Companies with no prior retina footprint are placing major bets. The conversation covers why, and what comes next.
Donald J. D’Amico, MD, then joins to go beyond the press release on the BRUNELLO Phase 2b/3 results for remigromig (Merck) in DME. He explains the Wnt pathway, why the PDR signal is permissive rather than causative, why ranibizumab 0.5mg was the only valid active comparator, how AI accelerated antibody development, and why he sees remigromig as the beginning of a new era in retinal pharmacology, not a one-time event.
The episode closes with RetinUp producers Laura Brown and Liz Hogan joining John and Scott to reflect on year one, what surprised them, and where RetinUp goes from here.
Hosts: John Kitchens, MD, Scott Krzywonos
Topics Covered
Big Pharma Comes to Retina
Four major deals in eighteen months: Merck/EyeBio (up to $3B, 2024), Eli Lilly/Adverum Biotechnologies (up to 262M, 2025), Biogen/Apellis (5.6B, 2026), AbbVie/RegenxBio licensing partnership (up to $1.75B). Of these, only Apellis had an approved drug at time of acquisition.
Why retina: aging patient population, novel biology, a proven track record of drug development (anti-VEGF), and a compressed window between Phase 2 and approval for diseases with clear endpoints. Retina is also a specialty where institutional relationships and a surgical infrastructure matter — the same reasons Alcon’s Neurotech acquisition makes sense.
What it signals: the gold rush is not over. Kodiak Sciences, with a multi-indication BLA in Q4 2026, is a prime acquisition target. Earlier-stage companies like Ollin BIo (noted for strong science and team) represent a lower-price entry point.
The human infrastructure point: talent migration has accelerated. People from established companies are moving to acquirees or to smaller companies that may themselves be acquired. Keeping the original team intact post-acquisition — as Biogen did with Apellis leadership — matters.
EyeBio founders David R. Guyer, MD, and Tony Adamis, MD: John reflects on their track record — co-founders of Eyetech Pharmaceuticals (pegaptanib, the first approved anti-VEGF), now at Merck with remigromig and tiespectus in the pipeline.
BRUNELLO Deep Dive with Donald J. D’Amico, MD
Study recap: remigromig 0.5 mg and 0.8 mg monthly vs. ranibizumab 0.5 mg monthly in DME with BCVA 24–75 letters and CST 325 µm or greater; 25% previously treated; primary endpoint BCVA change at week 52; both doses met non-inferiority.
The Wnt pathway: an evolutionarily conserved pathway with tissue-specific roles in blood-retinal barrier maintenance via the FZD4 receptor in retinal and brain vasculature. The natural agonist, norrin, has been notoriously difficult to mimic pharmacologically because it must simultaneously activate FZD4 and two epitopes of LRP5. Remigromig achieves this with a tetravalent, trispecific antibody — two arms to FZD4, one each to the LRP5 epitopes. A genuine pharmacological achievement.
The PDR signal: 6.1–6.7% PDR in remigromig arms vs. 0.9% with ranibizumab. Dr. D’Amico’s view: permissive, not causative. Remigromig is not anti-neovascular; it simply does not suppress PDR the way anti-VEGF does. Comparing to true sham controls in RISE/RIDE (16.3% PDR at one year) and VIVID/VISTA (11.1% at two years), remigromig’s PDR rate appears superior to natural history. Additionally, blood-retinal barrier restoration may itself have some anti-neovascular effect. Nothing in the current data suggests remigromig causes or accelerates PDR.
Why ranibizumab 0.5 mg as comparator: a non-inferiority trial requires an active comparator with an established non-inferiority margin and a primarily monthly dosing label. Ranibizumab is the only drug that meets this criterion. The 0.5 mg dose reflects international standard (US uses 0.3 mg); the trial will be hopefully used for global approval.
Combination and duration questions: remigromig was dosed monthly in BRUNELLO, but duration of effect is unknown. Dr. D’Amico raises the possibility that three monthly doses could produce six-to-eight months of efficacy. Combination with anti-VEGF is the logical next step; the mechanism is orthogonal, not competitive. BAROLO companion study expected Q1–Q2 2027.
Looking ahead: AI (specifically AlphaFold) played a meaningful role in remigromig’s antibody development by enabling prediction of three-dimensional polypeptide structure — one reason novel antibody development is accelerating. Other potential indications include RVO, wet AMD, uveitic macular edema, and postoperative CME.
RetinUp Year One: Reflections from the Team
Laura Brown, producer: came in knowing nothing about retina; learned by osmosis; continues to find eyeballs mildly distressing. Hopes for live recording at future meetings (specifically, Hawaii).
Liz Hogan, producer: surprised by how welcoming industry partners were from day one; credits John and Scott’s standing in the field with making early conversations easier. Notes that breaking news episodes — sometimes turned around in under 12 hours — are an industry best, and calls out Laura specifically for being reachable at all hours.
John Kitchens, MD: proud of the editorial independence, the quality of guests as educators, and the speed of breaking news coverage. Wants to move to weekly episodes and expand into human interest stories — not just data, but the people behind the field.
Scott Krzywonos: credits Liz for herding the cats on breaking news days; credits John for cultivating industry relationships built on genuine win-win thinking and unpaid goodwill over many years.
Year two outlook: more frequent episodes, possibly additional content channels, continued breaking news coverage, and more human interest storytelling.
Key Takeaways
The retina acquisition wave is not over. Merck, Lilly, Biogen, and AbbVie have all placed bets; Kodiak and others remain attractive targets.
EyeBio’s founders — David Guyer, MD, and Tony Adamis, MD — have now brought two transformative retina drug classes to the field. Remigromig represents a credible second act.
Remigromig’s PDR signal is permissive, not causative; cross-trial comparisons suggest remigromig patients fare better than natural history controls. The mechanism is orthogonal to anti-VEGF and is likely to be additive in combination.
Year one of RetinUp: 4,786+ downloads, a year of breaking news episodes, and a field that happened to produce more clinical data in twelve months than most specialties see in a decade.
Credits
Production & Marketing: Laura Brown | Business Operations: Liz Hogan
🎧 Listen at RetinUp.com | Apple Podcasts | Spotify | YouTube
Breaking News: Alcon Acquires Neurotech
2026/10/21
Two pieces of news today, October 21, 2026.
Alcon announced the acquisition of Neurotech Pharmaceuticals for $550 million upfront, with additional milestone payments possible. John Kitchens, MD, and Scott Krzywonos break down why the pairing makes sense, what Alcon’s OR infrastructure could mean for Encelto’s adoption, and where the reimbursement path goes from here.
Priovant Therapeutics (Roivant Sciences) also announced positive Phase 3 CLARITY results for brepocitinib in non-infectious uveitis. Both trials met their primary endpoints. Scott and John review what this means alongside vamikibart, and why the two drugs are more complementary than competitive.
Hosts: John Kitchens, MD, Scott Krzywonos
Topics Covered
Alcon Acquires Neurotech for $550 Million
Encelto (revakinagene taroretcel-lwey) is the only approved treatment for MacTel 2 — an estimated 25,000 US patients, 2,000–3,000 newly diagnosed annually. It’s an OR-delivered encapsulated cell therapy implant requiring surgical expertise, OR relationships, and reimbursement infrastructure. Alcon has all three.
Adoption to date: more than 100 surgeries and 700+ patients in the patient portal as of March 2026. Alcon’s network is expected to expand the number of centers offering Encelto significantly.
Reimbursement: buy-and-bill at approximately $200,000+ is a meaningful risk for surgery centers. Neurotech’s specialty pharmacy model removed that risk but limited center economics. Alcon’s infrastructure may help centers navigate both pathways.
Centers of excellence: neither academic nor private practice dominates. John cites Drew Somerville, MD, a private practice retina specialist in Evansville, Indiana, who built out an Encelto program independently. Alcon can replicate that at scale.
Alcon’s broader strategy: Lumithera (photobiomodulation), Aurion Biotech (corneal cell therapy), RxSight partnership (light adjustable lens), and now Neurotech — a consistent pattern of investing in disease-specific technology with a procedural delivery component.
Brepocitinib / CLARITY (Priovant Therapeutics / Roivant Sciences)
Brepocitinib is an oral TYK2/JAK1 inhibitor, 45mg once daily, already approved for psoriatic arthritis. CLARITY is the sNDA program for non-infectious uveitis (NIU).
Study design: CLARITY-1 (N=166) and CLARITY-2 (N=204); 48-week double-masked; mandatory steroid taper to zero — more aggressive than prior NIU trials.
Results: cumulative treatment failure at week 48 was 35.4% vs. 78.7% in CLARITY-1 and 32.4% vs. 77.8% in CLARITY-2. Pooled steroid-free quiescence: 62% vs. 20%. Macular edema resolution among patients with baseline ME: 42% vs. 4.8%. Median time to treatment failure not reached in the brepocitinib arm vs. approximately 12 weeks on placebo.
Regulatory path: sNDA planned 1H 2027.
How it fits with vamikibart: brepocitinib is systemic — whole-eye disease control; vamikibart is intravitreal — macular edema specifically. Complementary, not competitive. Patients with refractory macular edema despite systemic control are the logical combination candidates.
Key Takeaways
Alcon’s acquisition of Neurotech gives Encelto the OR infrastructure, relationships, and reimbursement support it needs to scale. Good for patients, and for the long-term viability of a therapy with no real comparator.
MacTel 2 is likely underdiagnosed. With Alcon behind the treatment, earlier detection and expanded identification are reasonable expectations.
Brepocitinib delivers the strongest uveitis Phase 3 data seen to date — 62% steroid-free quiescence vs. 20% placebo under an aggressive steroid taper. sNDA in 1H 2027.
Brepocitinib and vamikibart address different aspects of uveitis and are likely to be used together in difficult patients.
Credits
Production & Marketing: Laura Brown | Business Operations: Liz Hogan
🎧 Listen at RetinUp.com | Apple Podcasts | Spotify | YouTube
Breaking News: LUCIA Misses in Wet AMD — EyePoint Shifts to DME
2026/10/19
Breaking news: EyePoint Pharmaceuticals announced this morning that LUCIA, the second pivotal Phase 3 trial of Duravyu (vorolanib, EYP-1901) for wet AMD, did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label aflibercept. EyePoint is shifting resources away from its wet AMD program and re-focusing efforts on its DME program.
John Kitchens, MD, and Scott Krzywonos break down the data — what the secondary endpoints showed, what the safety profile looked like across both trials, and what LUCIA means for TKIs as a class. The conversation closes with a look at why EyePoint still believes Duravyu has a future in DME, and what the COMO and CAPRI trials will need to show.
Hosts: John Kitchens, MD, Scott Krzywonos
Topics Covered
LUCIA Topline Results
Primary endpoint: not met. LUCIA did not achieve statistical non-inferiority in mean change in BCVA vs. aflibercept 2mg every eight weeks in 475 patients with wet AMD.
Secondary endpoints met: 38% reduction in treatment burden vs. aflibercept (nominal p less than 0.0001); 52% of Duravyu eyes supplement-free through week 56; 71% received zero or one supplement through week 56. Visual improvement was demonstrated — the drug works biologically — but not to the margin required for non-inferiority.
Both LUGANO and LUCIA showed the same pattern: durability and anatomic control with treatment burden reduction, but not the vision bar that a regulatory submission requires.
Pooled safety: retinal hemorrhage 4.7% (Duravyu) vs. 1.5% (aflibercept); vitreous hemorrhage 2.3% vs. 0.0%; cataract rate comparable between arms. No increase in inflammation with redosing.
What the LUGANO Pattern Means
In LUGANO, nine patients in the treatment arm drove the primary endpoint miss — six with GA progression, one with a repaired retinal detachment, two with glaucoma. Whether LUCIA showed a similar subgroup pattern or a broader, more global finding was not addressed on the investor call. EyePoint says additional analyses of pooled LUGANO and LUCIA data are ongoing.
John’s read: the hemorrhage signal is worth watching for TKIs broadly. Extended dosing intervals without close monitoring may allow lapse of disease control in patients prone to hemorrhage. Identifying those patients earlier — and either monitoring them more closely or switching agents — will be important as TKIs move toward approval.
What It Means for TKIs
Duravyu’s wet AMD failure does not close the book on TKIs. Axpaxli (Ocular Therapeutix) had a positive superiority study in SOL-1, albeit with an unusual study design that selected for highly responsive patients. What the EyePoint data add is real-world texture: TKIs produce durability and anatomic control, but the vision bar in wet AMD may be harder to clear than expected.
The extended interval also raises monitoring questions that approval studies don’t fully answer. Understanding which patients tolerate 6-month dosing — and which don’t — may be essential before widespread clinical adoption.
The DME Pivot
EyePoint is refocusing resources on Duravyu in DME. The rationale: DME is a multifactorial, inflammatory disease where Duravyu’s mechanism may be more relevant than in wet AMD. The Phase 2 VERONA trial met its primary endpoint in DME with extended time to first supplemental injection.
Two pivotal Phase 3 DME trials — COMO and CAPRI — are ongoing. Topline data expected Q4 2027.
John’s observation: treatment burden reduction in working-age DME patients carries a different weight than in wet AMD — fewer injections means less time off work, which matters to patients and their employers. DME is also a more forgiving disease for subretinal hemorrhage and does not carry the same atrophy risk that complicated both wet AMD trials.
Key Takeaways
LUCIA missed its primary endpoint. EyePoint is winding down the wet AMD program and pivoting to DME. The wet AMD TKI chapter for Duravyu is all but closed.
The secondary data confirm Duravyu’s biological activity — 52% supplement-free at week 56 — but biological activity and regulatory approval are not the same thing.
TKIs as a class still have a future, but the hemorrhage and monitoring data from LUGANO and LUCIA may inform how Axpaxli is positioned if it reaches approval.
COMO and CAPRI in DME read out Q4 2027. DME may be where the TKI mechanism ultimately finds its clinical home.
Credits
Production & Marketing: Laura Brown | Business Operations: Liz Hogan
🎧 Listen at RetinUp.com | Apple Podcasts | Spotify | YouTube
AAO 2026 Recap + Vitrectomy for Floaters with Christina Weng, MD, MBA
2026/10/15
John Kitchens, MD, and Scott Krzywonos recap the American Academy of Ophthalmology 2026 Annual Meeting in New Orleans — a meeting that delivered on science even as a hurricane threatened attendance. Zenkuda’s 6-month durability data, a first-in-class Wnt agonist for DME, a gene therapy filing for X-linked RP, and a photovoltaic retinal implant nearing FDA review. Plus, a suprachoroidal access device worth watching from SJJ Solutions.
Then: Christina Y. Weng, MD, MBA — Professor & Alice R. McPherson Retina Research Foundation Chair in Ophthalmology at Baylor College of Medicine and host of the Retina TL;DR podcast — joins to discuss the cultural and clinical shift around vitrectomy for floaters: who’s a candidate, how the risk-benefit calculus has changed, and what’s driving more academic centers to finally embrace the surgery.
Hosts: John Kitchens, MD | Scott Krzywonos
Guest: Christina Y. Weng, MD, MBA
TOPICS COVERED
AAO 2026: What Had the Room Buzzing
Zenkuda (tarcocimab tedromer) — Kodiak Sciences
Phase 3 DAYBREAK results confirmed noninferiority to aflibercept in wet AMD. 54% of patients reached 6-month dosing under strict treat-to-dryness retreatment criteria — criteria that mirror how many retina specialists already practice. Kodiak plans to file a multi-indication BLA in Q4 2026 across wet AMD, DR, and RVO simultaneously. The companion DAYBREAK arm, KSI-501 (tabirafusp-ted, an IL-6/VEGF bispecific), also met its noninferiority endpoint, though the rationale for IL-6 in wet AMD is weaker than in DME or uveitis.
Remigromig (MK-3000) — Merck | BRUNELLO Trial
Donald J. D’Amico, MD, presented one-year results from the pivotal Phase 2b/3 BRUNELLO study. Remigromig, a trispecific Wnt pathway agonist, demonstrated noninferior visual acuity gains versus monthly ranibizumab in DME — the first biologic with a novel mechanism to clear that bar. New-onset PDR occurred in roughly 6.5% of remigromig patients versus under 1% with ranibizumab, a difference that warrants monitoring but does not, in John’s read, mean the drug causes PDR. It simply doesn’t suppress it the way anti-VEGF does. Merck says additional safety analyses are underway. Tiespectus (MK-8748), Merck’s Tie2 agonist/VEGF inhibitor bispecific, is now enrolling in the pivotal Phase 2b/3 MALBEC trial for wet AMD.
Vamikibart — Genentech/Roche | MEERKAT and SANDCAT
One-year Phase 3 data from the MEERKAT and SANDCAT trials showed sustained improvements in visual acuity and central subfield thickness in uveitic macular edema. The FDA has accepted Genentech’s BLA, with an approval decision expected by July 2027. Ozurdex and Iluvien are approved intravitreal options for uveitic macular edema, but both are steroids — vamikibart would be the first non-steroidal intravitreal treatment for the condition.
Laru-zova — Beacon Therapeutics | VISTA Trial
Robert Sisk, MD, presented Phase 3 VISTA results: 31% of patients in the high-dose group and 24% in the low-dose group gained at least 15 letters in low luminance visual acuity at 12 months. Beacon plans to begin a rolling FDA submission. If approved, laru-zova would be the first approved gene therapy for X-linked retinitis pigmentosa and only the second ocular gene therapy since Luxturna (Spark Therapeutics) in 2017. Questions remain around dose selection, durability, cost, and access.
PRIMA Photovoltaic Retinal Implant
The PRIMA system — a wireless subretinal photovoltaic implant paired with near-infrared-projecting glasses — received a detailed safety update covering macular holes, hemorrhage, and atrophy expansion. Trade-offs were more favorable than expected, with patients still using the device several years post-implant. Patients average 62 hours of post-implant training before seeing functional benefit. European approval is active; FDA review is possible before the end of 2026.
SJJ Solutions — Suprachoroidal Access Device
John was invited to see a pre-launch suprachoroidal access device from SJJ Solutions, the same company that makes the zero-fill needles used in his clinic. The device guides a standard needle to the suprachoroidal space reliably regardless of scleral thickness, using a limbus-hugging guide and an incremental advancement ramp. No financial relationship.
Vitrectomy for Floaters with Christina Y. Weng, MD, MBA
The cultural shift around floaterectomy has been two decades in the making, and Christina Weng has been a central figure in moving it forward. Three drivers she identifies: patients with debilitating symptoms are driving awareness through word of mouth; the premium IOL era has raised the bar on visual quality, making floaters more conspicuous and less tolerable; and advances in surgical technology — higher cut rates, smaller gauge, optimized fluidics — have improved the risk-benefit ratio on both sides of the equation.
On patient selection: Christina requires at least six months of symptoms before operating — time for neuroadaptation to run its course. Her ideal candidate is symptomatic, pseudophakic, with a complete PVD, few comorbidities, and realistic expectations. That said, she operates on patients who don’t meet every criterion, with appropriate counseling. In phakic patients, she often proposes combined surgery with a cataract colleague, or defers until after cataract surgery when a PVD may have occurred.
The Sebag legacy: John cites the work of Jerry Sebag, MD, on contrast sensitivity and floaters — research showing that vitreous opacities can degrade contrast sensitivity to a degree comparable to a 2–3+ nuclear sclerotic cataract. Insurance coverage has followed the science: this is not a cash-pay elective. It’s a covered surgery.
The economics conversation: Academic centers have historically been slower to adopt elective vitreoretinal surgery, and the stigma around floaterectomy — partly clinical, partly financial — has been part of that reluctance. Christina is candid that declining reimbursements and OR access constraints are shaping case mix decisions everywhere, academic and private alike. The shift toward doing more elective cases at academic centers is real, and she frames it as compatible with — not in conflict with — patient-first priorities.
KEY TAKEAWAYS
Zenkuda’s strict treat-to-dryness protocol yielded 54% six-month durability. Kodiak is filing across wet AMD, DR, and RVO simultaneously in Q4 2026.
Remigromig doesn’t cause PDR — it just doesn’t treat it. The path forward is likely combination use with anti-VEGF, not substitution.
Vamikibart could give UME patients their first non-steroidal intravitreal option. FDA decision expected July 2027.
Laru-zova may be the second approved ocular gene therapy in a decade. For XLRP some patients who’ve been told there’s nothing, the conversation has changed.
Vitrectomy for floaters works, insurance covers it, and the risk-benefit math is better than ever. The remaining hurdle is cultural — particularly in academic settings — and that’s shifting.
SPONSORS
Today’s episode is made possible by Genentech, maker of Vabysmo (faricimab-svoa). Hear peer perspectives and case studies — including Dr. David Eichenbaum unpacking what drying looked like in a real-world DME patient treated with Vabysmo — in their Purple Chair Series at vabysmo-hcp.com.
This RetinUp podcast is brought to you by Alcon, a global leader in eye care with an industry-leading breadth of surgical products and solutions, including Unity VCS. Learn more at unityvcs.com.
Astellas is focused on the patients who need help the most — those whose lives are impacted by declining or lost vision with no or few therapies available. Learn more at Astellas.com.
CREDITS
Production & Marketing: Laura Brown | Business Operations: Liz Hogan
🎧 Listen at RetinUp.com | Apple Podcasts | Spotify | YouTube
The 2026 Data Recap — What to Watch at AAO Next Week
2026/10/01
John Kitchens, MD, and Scott Krzywonos take stock of the biggest retina data readouts of 2026 — from a superiority study from Ocular Therapeutix to a Kodiak comeback and a gene therapy from Beacon that could be the first approval for an inherited retinal disease since Luxturna in 2017. Also discussed: topline data for remigromig (Merck/EyeBio) and Duravyu (EyePoint).
The conversation covers what each dataset means in clinical terms, which presentations at AAO are must-attends, and what happens when all these new mechanisms — TKIs, ABC polymers, Wnt pathway agonists, IL-6 inhibitors, and gene therapy — arrive in clinic around the same time.
The episode closes with a broader question: are we entering an era of retina that looks more like oncology, where doctors match individual patients to specific treatments rather than relying on trial and error?
Hosts: John Kitchens, MD, Scott Krzywonos
Topics Covered
Axpaxli / SOL-1 (Ocular Therapeutix)
A superiority study — rare in retina. Primary endpoint at month 9: Axpaxli patients maintained vision at a significantly higher rate than those treated with a single injection of aflibercept.
Study design selected for highly responsive patients, which may have produced a stronger-than-expected control arm response. More than half of aflibercept control patients went six months before needing rescue treatment.
Axpaxli holds a Special Protocol Assessment (SPA) from the FDA, which should support a cleaner approval pathway. NDA filing planned for 2026.
Darius M. Moshfeghi, MD, presents SOL-1 results at AAO Subspecialty Day, Friday, October 9, 4:35 PM.
Duravyu / LUGANO (EyePoint Pharmaceuticals)
Phase 3 non-inferiority study for wet AMD. Nine patients in the treatment arm drove the primary endpoint miss.
The LUCIA companion study remains the decisive data set; if positive, expect an NDA submission in 1H 2027.
Carl D. Regillo, MD, FACS, presents LUGANO results at AAO Subspecialty Day, Friday, October 9, 4:30 PM.
Zenkuda / DAYBREAK (Kodiak Sciences)
Phase 3 wet AMD study; three arms — Zenkuda (four monthly loading doses, then PRN with zero-fluid-tolerance AI retreatment criteria), tabirafusp-ted (four monthly loading doses, then every-other-month proactively), and aflibercept (three monthly loading doses, then every eight weeks).
Zenkuda: 7.2-letter vision gain vs. 7.6 for aflibercept. 54% of patients reached 6-month dosing at year 1 under strict treat-to-dryness criteria. 0% intraocular inflammation.
The key modification from KSI-301: Zenkuda includes 20% free drug for immediate drying effect, with 80% ABC-conjugated drug providing the approximately 20-day half-life and durability.
Tabirafusp-ted also met its primary endpoint, but added no additional vision gains vs. aflibercept. IL-6 inhibition may have a stronger case in DME and uveitic macular edema; ALTO Phase 3 in DME is actively enrolling.
Kodiak plans a Q4 2026 three-indication BLA for Zenkuda (wet AMD, diabetic retinopathy, RVO).
Charles C. Wykoff, MD, PhD, presents DAYBREAK results at AAO Subspecialty Day, Friday, October 9, 4:40 PM.
Remigromig / BRUNELLO (Merck)
Phase 2b/3 non-inferiority study for DME. Both doses (0.5 mg and 0.8 mg) demonstrated non-inferiority to monthly ranibizumab 0.5 mg at week 52.
A Wnt pathway agonist — not an anti-VEGF. Targets endothelial cell tight junctions in the retinal vasculature. Higher rates of PDR and vitreous hemorrhage in the remigromig arms vs. control; full data not yet seen beyond the press release.
John's read: likely an add-on to anti-VEGF, not a replacement. Anti-VEGF co-therapy should mitigate the proliferative signal. Target population: the roughly 40% of DME patients with persistent edema despite treatment (per DRCR Protocol I and Protocol T).
Monthly dosing is a practical disadvantage vs. Ozurdex; absence of cataract and IOP risk is the advantage.
BAROLO companion study expected Q1–Q2 2027.
Donald J. D'Amico, MD, presents BRUNELLO results at AAO Subspecialty Day, Saturday, October 10, 5:10 PM.
Laru-zova / VISTA (Beacon Therapeutics)
Pivotal Phase 3 gene therapy for X-linked retinitis pigmentosa — the first XLRP trial to meet its primary endpoint, and the first potential gene therapy approval in retina since Luxturna in 2017.
Primary endpoint: low luminance visual acuity responder rate (gain of 15+ letters at month 12). High-dose arm: 31%. Low-dose arm: 24%. Untreated control: 0%.
XLRP is more prevalent than RPE65-mediated LCA and has a characteristic inheritance pattern that may make family-based identification more tractable. Enrollment required VA of 20/32 or better — earlier diagnosis and genetic testing are prerequisites for treatment.
Robert A. Sisk, MD, FACS, FASRS, presents VISTA first-time results at AAO Subspecialty Day, Saturday, October 10, 4:13 PM.
The Bigger Picture: Precision Retina?
The arrival of multiple new mechanisms in close succession — TKIs, ABC polymers, Wnt agonists, IL-6 inhibitors, gene therapy — raises a question Charles C. Wykoff, MD, PhD, floated on the Kodiak investor call: is retina approaching an oncology-style era where specific patients are matched to specific treatments?
John's view: we're not there yet. The DRCR Retina Network is well-positioned to run the head-to-head comparison studies that would generate that evidence. AI may eventually help identify disease phenotypes that predict response to one mechanism vs. another — but the data to train it on don't exist yet.
Key Takeaways
Five major Phase 3 datasets in one year — SOL-1, LUGANO, DAYBREAK, BRUNELLO, and VISTA — each with different mechanisms, endpoints, and implications. Friday and Saturday afternoon at AAO Subspecialty Day are the sessions to be in the room for.
TKIs and Zenkuda are both targeting durability in wet AMD but via different mechanisms; real-world data will tell us whether the trial results hold outside controlled conditions.
Remigromig's safety signal in BRUNELLO will be the central topic at Dr. Don D'Amico's Saturday talk; the full data, not just the press release, will determine how seriously practices take the PDR risk.
VISTA represents a potential turning point for inherited retinal disease — and a reminder that the stakes in retina extend well beyond market dynamics.
Credits
Production & Marketing: Laura Brown | Business Operations: Liz Hogan
🎧 Listen at RetinUp.com | Apple Podcasts | Spotify | YouTube
Sponsors
This episode is made possible by Genentech, maker of Vabysmo (faricimab-svoa). Purple Chair series at Vabysmo-HCP.com.
This episode is brought to you by Neurotech, makers of Encelto (revakinagene taroretcel-lwey). Learn more at encelto.com/ecp.
Breaking News: Kodiak's DAYBREAK Hits — Zenkuda and Tabirafusp-ted Both Positive
2026/09/28
Breaking news: Kodiak Sciences announced this morning that both Zenkuda (tarcocimab tedromer) and tabirafusp-ted (KSI-501, tabirafusp alfa tedromer) met their primary endpoints in the Phase 3 DAYBREAK study in wet AMD — non-inferiority in vision gains vs. aflibercept at 1 year. Kodiak plans a Q4 2026 BLA filing for Zenkuda, covering five positive Phase 3 studies across wet AMD, diabetic retinopathy, and RVO.
John Kitchens, MD, and Scott Krzywonos break down what makes DAYBREAK's design unusual, why Kodiak's comeback from the KSI-301 miss matters, what 54% of patients on 6-month dosing actually means in a real-world context, and what the tabirafusp-ted data suggest about where IL-6 inhibition fits in retina.
Detailed results will be presented at AAO Subspecialty Day by Charles C. Wykoff, MD, PhD, on Friday, October 9, at 4:40 PM local time, New Orleans.
Hosts: John Kitchens, MD, Scott Krzywonos
Topics Covered
DAYBREAK: What the Data Show
Study design: Phase 3; treatment-naive wet AMD patients only; three arms — Zenkuda (four monthly loading doses, then PRN based on zero-fluid-tolerance retreatment criteria based on AI volumetric data), tabirafusp-ted (four monthly loading doses, then every-other-month proactively with monthly dosing if needed), and aflibercept 2mg (three monthly loading doses, then every eight weeks); primary endpoint: mean BCVA change from weeks 40 to 48.
Zenkuda primary endpoint: met (p=0.0007). Vision gains: 7.2 letters (Zenkuda) vs. 7.6 letters (aflibercept). Central subfield thickness reduction: approximately 135 µm in both arms. Durability: 54% of Zenkuda patients reached 6-month dosing at year 1; 62% reached at least 5 months.
Tabirafusp-ted primary endpoint: also met (p=0.0036). Anatomical key secondary endpoint also met (p0.0001). No additional vision gains vs. aflibercept despite the added IL-6 inhibition.
Safety: Zenkuda showed 0% intraocular inflammation and a 0.5% cataract adverse event rate (vs. 0.9% for aflibercept). Tabirafusp-ted showed 0% cataract adverse events.
What Makes This Design Different
Zero-fluid-tolerance retreatment criteria: most trials allow some residual fluid in pursuit of extended intervals. DAYBREAK allowed none — any fluid on AI volumetric analysis triggered retreatment. This is closer to how most retina specialists actually treat in clinic, which may narrow the gap between trial outcomes and real-world results.
AI-assisted retreatment: Kodiak used an AI volumetric fluid tool assessing the central 3 mm of the OCT to determine retreatment eligibility. The combination of strict criteria and a 20-day half-life for Zenkuda is what may drive the durability signal.
Previously treated patients: DAYBREAK enrolled treatment-naive patients only. The companion ALTO Phase 3 study will assess both treatment-naive and previously treated patients with tabirafusp-ted in DME, actively enrolling now.
Kodiak's Comeback from KSI-301
KSI-301, Kodiak's prior ABC-platform agent, missed its primary endpoint. Kodiak modified the approach with Zenkuda, allowing some free drug alongside the conjugated biopolymer to produce immediate effect on loading, then relying on the conjugated drug for durability. The ~20-day intravitreal half-life of Zenkuda exceeds what is seen with conventional anti-VEGF agents.
What the Tabirafusp-ted Data Mean for IL-6
No additional vision gains with tabirafusp-ted vs. aflibercept despite monthly/bimonthly dosing. John's read: IL-6 may not add meaningful benefit in treatment-naive wet AMD. Better indications likely exist: uveitic macular edema and DME (where vascular leakage and inflammation are more tightly linked). Post-hoc analyses to identify wet AMD subgroups that might benefit are planned.
What's Next
Zenkuda BLA: Q4 2026 filing, covering five positive Phase 3 studies across wet AMD, diabetic retinopathy, and RVO.
ALTO: Phase 3 study of tabirafusp-ted in DME; enrolling now; includes both treatment-naive and previously treated patients.
Full data presentation: Charles C. Wykoff, MD, PhD, presents DAYBREAK results at AAO Subspecialty Day, Friday, October 9, 4:40 PM, New Orleans.
Key Takeaways
Both Zenkuda and tabirafusp-ted met their primary endpoints in DAYBREAK — Kodiak's comeback from the KSI-301 miss is complete, at least clinically.
54% of Zenkuda patients on 6-month dosing under zero-fluid-tolerance criteria is a meaningful durability signal, and the strict retreatment protocol makes these results more directly comparable to real-world practice than most trials.
Tabirafusp-ted's vision data in wet AMD don't support IL-6 as a meaningful add-on in treatment-naive patients; DME and uveitic macular edema remain the more compelling targets.
Kodiak plans a Q4 2026 BLA filing for Zenkuda across three indications. If approved, this would be an important new mechanism in wet AMD.
Credits
Production & Marketing: Laura Brown | Business Operations: Liz Hogan
🎧 Listen at RetinUp.com | Apple Podcasts | Spotify | YouTube
Breaking News: Merck's Remigromig Hits Primary Endpoint in BRUNELLO for DME [Corrected]
2026/09/25
Breaking news: Merck announced this morning that remigromig (MK-3000), its investigational tetravalent tri-specific Wnt pathway agonist, met the primary endpoint of the Phase 2b/3 BRUNELLO trial for diabetic macular edema. Both the 0.5 mg and 0.8 mg doses independently demonstrated non-inferiority to 0.5 mg ranibizumab monthly at week 52.
John Kitchens, MD, and Scott Krzywonos break down the topline data, the safety signals to watch (and how they might be mitigated in real-world treatment), where remigromig fits alongside anti-VEGF and steroid therapy, and what the BAROLO companion study needs to show before Merck can engage regulators for approval.
Full data presentation by Donald J. D'Amico, MD, at AAO Subspecialty Day, Saturday, October 10, 5:10 PM local time, New Orleans.
Editors' Note: A previous version of this episode understated the complexity of the Wnt signalling pathway. It has been edited for accuracy.
Hosts: John Kitchens, MD, Scott Krzywonos
Topics Covered
BRUNELLO: What the Data Show
Trial design: randomized, double-masked Phase 2b/3; 984 participants with DME; three arms — remigromig 0.5 mg, remigromig 0.8 mg, and ranibizumab 0.5 mg (active control); all dosed monthly; primary endpoint: mean change from baseline in BCVA at week 52.
Primary endpoint: met. Both doses of remigromig independently demonstrated non-inferiority to ranibizumab at week 52.
Safety signals: higher rates of proliferative diabetic retinopathy (PDR), vitreous hemorrhage, and treatment discontinuations due to adverse events in the remigromig arms vs. ranibizumab. Further analyses are underway. Merck described both doses as generally well tolerated.
The Mechanism: What the Wnt Pathway Does
Remigromig is not an anti-VEGF, but rather a tetravalent, tri-specific antibody designed to activate the Wnt pathway, which is involved in the repair and maintenance of the blood-retinal barrier. The target: endothelial cell tight junctions in the retinal vasculature — specifically relevant in DME, where vascular leakage is the central pathology.
Where It Fits: Combination vs. Monotherapy
BRUNELLO was a monotherapy study — remigromig was not tested in combination with anti-VEGF. Why: a combination study would likely have required a superiority design (a higher bar than noninferiority). Merck's clearest regulatory path was monotherapy noninferiority first.
If approved, John expects remigromig to function as an add-on, not a replacement — similar to how a second-line glaucoma agent like brimonidine coexists with prostaglandin analogs. The target patient: the roughly 40% with persistent DME edema after anti-VEGF (per DRCR Protocol I and T data).
Ranibizumab is a defensible comparator: RIDE/RISE and Protocol T all-comers data show no statistically significant difference vs. aflibercept across the full population.
Competitive Context: Ozurdex and Tiespectus
If approved, remigromig may compete most directly with Ozurdex (dexamethasone intravitreal implant 0.7 mg, AbbVie) in the non-anti-VEGF DME add-on space. Monthly dosing is remigromig's disadvantage vs. Ozurdex's less frequent schedule; the absence of cataract and IOP risks is its advantage.
Tiespectus (MK-8748): Merck's second ophthalmology program — a bispecific antibody that directly activates Tie2 and inhibits VEGF. Being studied first in wet AMD. John's view: remigromig gets Merck on base; tiespectus has home run potential if the data hold.
What's Next
BAROLO: the companion Phase 2b/3 trial in DME; topline data expected Q1–Q2 2027. Remigromig is also being evaluated in SUPER TUSCAN, a Phase 2 proof-of-concept study in wet AMD and RVO. Any regulatory submission pathway for DME depends on the totality of BRUNELLO and BAROLO together.
Full data: Donald J. D'Amico, MD, presents BRUNELLO 1-year results at AAO Subspecialty Day, Saturday, October 10, 5:10 PM, New Orleans.
Key Takeaways
BRUNELLO hit its primary endpoint — remigromig is non-inferior to ranibizumab in DME, representing the first positive Phase 3 data for a non-anti-VEGF, non-steroid DME treatment.
The PDR and vitreous hemorrhage signals are real and need characterization; anti-VEGF co-therapy may be the practical mitigation, but that remains to be demonstrated in a combination study.
Remigromig is likely an add-on, not a replacement — the 40% of patients with persistent DME edema on anti-VEGF are the target population.
BAROLO data (Q1–Q2 2027) will determine whether Merck has a regulatory submission package. Tiespectus follows behind.
Credits
Production & Marketing: Laura Brown | Business Operations: Liz Hogan
🎧 Listen at RetinUp.com | Apple Podcasts | Spotify | YouTube
Breaking News: Beacon's Gene Therapy Laru-zova Hits Primary Endpoint in VISTA for XLRP
2026/09/23
Breaking news: Beacon Therapeutics announced positive topline data from the VISTA pivotal trial of laru-zova (laruparetigene zovaparvovec) for X-linked retinitis pigmentosa (XLRP) — the first gene therapy trial in XLRP to reach its primary endpoint.
John Kitchens, MD, and Scott Krzywonos break down the study design, the FDA-endorsed low luminance visual acuity endpoint, what the dose response data actually says (or doesn't say), and what could complicate the path to approval.
The VISTA data will be presented in full by Robert A. Sisk, MD, at AAO Subspecialty Day on Saturday, October 10, at 4:13 PM local time in New Orleans.
Hosts: John Kitchens, MD, Scott Krzywonos
Topics Covered
VISTA Trial: What the Data Show
Study design: 85 males aged 12–48 with XLRP; enrollment visual acuity 20/32 to no worse than 20/200; high- and low-dose arms compared with untreated control patients (no sham arm); 1-year primary endpoint.
Primary endpoint: low luminance visual acuity (LLVA) responder rate — defined as a gain of ≥15 letters at month 12. High-dose arm: 31% of patients reached this threshold. Low-dose arm: 24%. Untreated control arm: 0%. The differential between treated and untreated is the signal; the difference between dose arms is small.
Secondary endpoints: gain of ≥10 letters in LLVA (low dose 59%, high dose 48%, untreated 4%); mean macular sensitivity on microperimetry (statistically significant in the low dose, not the high dose).
Safety: described as good in the press release; no major safety signals reported.
The FDA-Endorsed Endpoint
LLVA measures vision under reduced light conditions — the primary functional deficit in XLRP. Standard BCVA is not well-suited for a disease where night vision failure is the central complaint.
Before study launch, Beacon likely aligned with the FDA on this endpoint — a pre-agreement that doesn't guarantee approval but confirms both parties entered the trial with shared expectations on how benefit would be measured.
Dose Response and Approval Path
The absence of a clear dose response — low dose slightly outperforming high dose on some endpoints — may raise FDA questions about dose selection. Gene therapy pharmacokinetics are not always linear, which provides some rationale. Manufacturing capacity and scalability will also be subject to scrutiny, given the novelty of the platform.
Beacon has announced plans to pursue regulatory submissions, including to the FDA.
Clinical Context
XLRP is more prevalent than RPE65-mediated LCA (the target of Luxturna, Spark Therapeutics) and has a characteristic X-linked inheritance pattern — affected males, carrier females — that may make family-based identification more feasible than prior inherited retinal disease programs.
Enrollment in VISTA required VA of 20/32 or better, which means earlier diagnosis and genetic testing will be essential to identify candidates before disease progression.
The first full data presentation: Robert A. Sisk, MD, Professor of Ophthalmology, Cincinnati Eye Institute/University of Cincinnati, presents VISTA first-time results at AAO Subspecialty Day, Saturday, October 10, 4:13 PM local time, New Orleans.
Key Takeaways
VISTA is the first gene therapy trial in XLRP to reach its primary endpoint — the first potential gene therapy approval in retina since Luxturna in 2017.
The FDA-endorsed LLVA endpoint reflects a deliberate effort to measure what actually matters to patients with XLRP: the ability to function in low light.
Earlier diagnosis and genetic testing will be prerequisites for treatment; the X-linked inheritance pattern may make family-based identification more tractable than prior IRD programs.
Full data at AAO Sub Day, October 10, 4:13 PM local time. More to come.
Credits
Production & Marketing: Laura Brown | Business Operations: Liz Hogan
🎧 Listen at RetinUp.com | Apple Podcasts | Spotify | YouTube
AAO 2026 Preview | Retina Subspecialty Day & the Talks Worth Showing Up For
2026/09/17
John Kitchens, MD, and Scott Krzywonos break down the AAO 2026 annual meeting in New Orleans (October 9–12) — whether it still matters, what to catch at Subspecialty Day, and which late-breaking Phase 3 data presentations could move the field. Each host shares their top four talks, and the Vitreoretinal View covers the surgical program.
A quick correction from the prior episode: the SOL-1 primary endpoint was at month 9, not month 6, as stated in our previous episode. Corrections welcome at [email protected].
Hosts: John Kitchens, MD, Scott Krzywonos
Topics Covered
AAO 2026: Does It Still Matter?
In-person attendance may be down post-COVID, but virtual access has expanded the meeting's reach significantly. Still a premier venue for late-breaking Phase 3 data and surgical education. New Orleans in October doesn't hurt.
John is on the podium in two places: the 2026 Debate Session (Friday, 2:45 PM — No Flap for Macular Hole) and a vitrectomy for floaters talk at Refractive Subspecialty Day. Plus, John pays tribute to Kirk Packo, MD — the legendary AAO debater — and his famous 2006 New Orleans talk calling out industry over Avastin access.
John's Top Four Talks
No. 4 — Friday, 5:10 PM: Ehsan Rahimy, MD, presents 36-month safety data from the PRIMA photovoltaic retinal implant trial in geographic atrophy. A European device that has hit mainstream news; risk of accelerating atrophy and debate over whether VA gains reflect true restoration or magnification make this one to watch.
No. 3 — Friday, 5:05 PM: Raj K. Maturi, MD, presents 12-month topline results from the Phase 2 ArMaDa trial of OCU-410, a modifier gene therapy for GA. Back-to-back with PRIMA; gene therapy for GA is the right target given the need for sustained delivery.
No. 2 — Saturday, 4:56 PM: Arshad M. Khanani, MD, MA, presents Phase 2 ELAAVATE data for RGX-314 (Regenxbio), a subretinal gene therapy for center-involved DME. Subretinal and suprachoroidal delivery routes both in development; data could signal what gene therapy for DME looks like before the Phase 3 wave hits.
No. 1 — Saturday, 5:10 PM: Donald J. D'Amico, MD, presents the BRUNELLO pivotal trial results for Remigromig (MK-3000, Merck) in DME — a Wnt pathway inhibitor that targets endothelial cell tight junctions rather than VEGF. A genuinely new mechanism; if it wins on VA and drying, it could be additive to anti-VEGF. Monthly ranibizumab as the comparator is defensible given the ride/rise data and Protocol T all-comers results. Merck's second program, tuspetinib (Tie2 activator, ANG1 pathway), is next up in the pipeline.
Scott's Top Four Talks
No. 4 — Friday, 8:30 AM: Jason Hsu, MD (Wills Eye Hospital), Top Journal Articles That Influenced My Practice. Not a single dataset — a real-world appraisal of what actually breaks through into practice.
No. 3 — Saturday, 4:37 PM: Nisha Acharya, MD, presents week 52 MEERKAT and SANDCAT data for vamikibart in uveitic macular edema. Week 16 data were presented at AAO 2025 and ARVO 2026; the 1-year read will be more definitive. Interesting wrinkle: higher dose won in MEERKAT, lower dose in SANDCAT.
No. 2 — Friday, 4:40 PM: Charles C. Wykoff, MD, PhD, presents the DAYBREAK Phase 3 trial for Kodiak Sciences — a three-arm study comparing KSI-301 (ABC anti-VEGF), KSI-501 (ABC anti-VEGF + anti-IL-6), and aflibercept. First time (we think) a sponsor has run two of their own candidates head-to-head against a control.
No. 1 — Saturday, 4:13 PM: Robert A. Sisk, MD, presents first-time pivotal VISTA trial results for laru-zova gene therapy (Beacon Therapeutics) for X-linked RP. Could be the second gene therapy approved in retina, and the first since Spark in 2017. Larger treatable population than RPE65-mediated LCA; safety around subretinal delivery in a pigmented retina will be key.
Vitreoretinal View: Surgical Talks at Subspecialty Day
Friday, 8:16 AM — Ninel Z. Gregori, MD: Subretinal administration of photoreceptor precursor cells in RP (Surgical Videos: Cool Cases and Complications). Subretinal photoreceptor delivery is distinct from gene therapy; anatomic and functional outcomes to watch.
Friday, 11:04 AM — Aleksandra V. Rachitskaya, MD: When to Worry and When Not to Worry About Retinoschisis. Schisis-related detachments are technically demanding with high PVR risk; looking for pearls on when to operate, laser options, tamponade choice.
Friday, 11:11 AM — Colin A. McCannel, MD: A Decade of 27-Gauge Vitrectomy Surgery. Less than 5% of US surgeons use 27-gauge; Alcon Unity system is optimizing flow and stiffness. Does 25-gauge still do everything 27 can without the compromises?
Saturday, 3:45 PM — Omesh P. Gupta, MD: Gore-Tex Scleral-Fixated IOL Technique (How Do I Do It).
Saturday, 3:52 PM — Murtaza K. Adam, MD: Yamane Technique IOL Placement (How Do I Do It).
Saturday, 4:06 PM — Glenn C. Yiu, MD, PhD: Suprachoroidal Injection Tips and Tricks. Increasingly relevant as suprachoroidal gene therapy delivery (RGX-314) advances and approved suprachoroidal steroid delivery matures.
Key Takeaways
AAO 2026 features an unusually dense late-breaking data slate: BRUNELLO, DAYBREAK, VISTA, MEERKAT/SANDCAT, PRIMA, and ArMaDa all read out at the same meeting.
BRUNELLO is the most mechanistically novel: a Wnt pathway inhibitor for DME that could eventually combine with anti-VEGF. VISTA is the most consequential for the inherited retinal disease field if positive.
Suprachoroidal delivery and 27-gauge vitrectomy are two surgical trends worth watching across multiple talks.
Correction: the SOL-1 primary endpoint was at month 9, not month 6, as stated on our previous episode.
Sponsors
This episode is made possible by Genentech, maker of Vabysmo (faricimab-svoa). Hear peer perspectives and case studies in the Purple Chair series, including Dr. David A. Eichenbaum on a real-world DME patient, at Vabysmo-HCP.com.
This episode is brought to you by Alcon, a global leader in eye care, including Unity VCS. Learn more at unityvcs.com.
Credits
Production & Marketing: Laura Brown | Business Operations: Liz Hogan
🎧 Listen at RetinUp.com | Apple Podcasts | Spotify | YouTube
Pipeline Check-In | Plus Carl Danzig, MD, on His Mid-Career Practice Switch
2026/09/03
John Kitchens, MD, and Scott Krzywonos take stock of the three biggest retina news stories of 2026 — the SOL-1 superiority data for Axpaxli (Ocular Therapeutix), the FDA approval of Lytenava (Outlook Therapeutics), and the LUGANO Phase 3 (near) miss for Duravyu (EyePoint Pharmaceuticals) — and look ahead to three imminent late-phase readouts that could reshape the field before year's end: DAYBREAK for Zenkuda (Kodiak), BRUNELLO for Restoret (Merck/EyeBio), and ARCHER 2 for vonaprument (Annexon).
Carl J. Danzig, MD, then joins for a candid conversation about leaving a solo retina practice after 14 years, navigating a non-compete, commuting across Alligator Alley, and what it actually costs — personally and professionally — to make a major mid-career professional transition. He recently joined Fort Lauderdale Eye Institute as one of four retina specialists, beginning to see patients there on August 24, 2026.
Hosts: John Kitchens, MD, Scott Krzywonos
Topics Covered
2026 Pipeline Check-In: Catching Our Breath
Axpaxli / SOL-1 (Ocular Therapeutix): first superiority study in retina; at week 36, 74% of Axpaxli patients maintained vision vs. 56% on a single aflibercept injection; at 1 year, 66% of Axpaxli patients had not lost 10 letters; NDA filing planned for 2026.
Lytenava (Outlook Therapeutics): FDA-approved July 2026 for wet AMD — the first FDA-approved ophthalmic formulation of bevacizumab; measured commercial rollout planned for Q4 2026; full commercialization early 2027. Key unresolved question: impact on compounded bevacizumab access, particularly for non-wet AMD indications including DME, CRVO, BRVO, and myopic CNV.
Duravyu / LUGANO (EyePoint Therapeutics): primary non-inferiority endpoint missed in the full dataset; attributed to nine outlier patients in the treatment arm with vision loss unrelated to wet AMD; ad hoc analysis excluding those patients showed non-inferiority; LUCIA companion study topline data expected Q4 2026.
2026 Pipeline Check-In: What's Coming
Kodiak Sciences — DAYBREAK (Zenkuda / KSI-501): Phase 3 non-inferiority study for wet AMD; two investigational arms vs. aflibercept; topline data expected September 2026. Kodiak's prior KSI-301 missed its primary endpoint; lessons learned informed DAYBREAK's design.
Merck — BRUNELLO (Restoret / MK-3000): Wnt pathway agonist antibody acquired via EyeBio; Phase 3 non-inferiority trial for DME; data expected within 4 to 6 weeks of recording; a second Merck program — an ang-1 upregulator and VEGF inhibitor designed to activate the Tie2 receptor rather than merely inhibiting ang-2 — follows behind.
Annexon — ARCHER 2 (vanoprument / ANX007): C1q complement inhibitor for GA; distinct mechanism from C3 (pegcetacoplan) and C5 (avacincaptad pegol) inhibitors; Phase 2 showed a visual acuity benefit without slowing lesion growth; hypothesis: C1q inhibition protects photoreceptors upstream of RPE loss, with atrophy reduction expected to emerge over 12–24 months; Phase 3 primary endpoint is vision preservation, not lesion growth.
Carl J. Danzig, MD, on Switching Practices at Mid-Career
Background: Temple University medical school, Wills Eye tumor research, residency at Charles Drew (transferred to SUNY Downstate after program closure), fellowship at UT Southwestern; joined Rand Eye Institute as the practice's first and only retina specialist in 2012.
Solo practice realities: PI on 59 clinical trials as a solo retina specialist in an anterior segment practice; required extensive coverage arrangements and leveraged a full network of South Florida retina colleagues; elected to Retina Society.
Why he left: felt like "salmon swimming against the current" in an anterior segment culture; outgrowing his role; needed partners, shared call, and a practice aligned with his research identity and professional goals.
The transition year: geographic restriction meant commuting from Fort Lauderdale to Bonita Springs (Advanced Retina Institute) — across Alligator Alley — Tuesday through Thursday most weeks; often away five to six nights at a time including commercial speaking and international meetings.
The real costs: income went to zero during the gap; anxiety about the non-compete timeline; mental load of solo parenting for his wife; being a diminished version of himself at home after long stretches away. "Phil Rosenfeld, MD, told me I jumped out of an airplane holding my family's hand and no one had a parachute."
Fort Lauderdale Eye Institute: one of four retina specialists; seven minutes from home; active clinical trial program; practice aligned with his values. First patient day: August 24, 2026.
Advice to anyone considering a mid-career move: know your worth, don't undervalue yourself, move sooner rather than later if the fit is wrong, and build your network before you need it.
Key Takeaways
The three biggest retina stories of 2026 — SOL-1, Lytenava, and LUGANO — set up a fall season with multiple Phase 3 readouts that could further reshape the treatment landscape.
Annexon's ARCHER 2 is the most mechanistically distinct GA program in Phase 3 — a C1q inhibitor targeting photoreceptors upstream of RPE loss.
Leaving a practice at mid-career is a financial, legal, logistical, and deeply personal decision — Carl Danzig's year-long transition is a useful blueprint for anyone considering it.
Network-building early in training is the single most durable investment a retina specialist can make.
Sponsors
This episode is made possible by Genentech, maker of Vabysmo (faricimab-svoa). Hear peer perspectives and case studies in the Purple Chair series at Vabysmo-HCP.com.
This episode is brought to you by Ocular Therapeutix, a biopharmaceutical company working to redefine the retina experience across drug development, treatment, and outcomes. Learn more at OCUTX.com.
Credits
Production & Marketing: Laura Brown | Business Operations: Liz Hogan
🎧 Listen at RetinUp.com | Apple Podcasts | Spotify | YouTube
Jay Duker, MD, on LUGANO and What Comes Next for Duravyu and EyePoint | Plus, Miles Harper on Successful and Failed OR Innovations
2026/08/20
Jay S. Duker, MD, President & CEO of EyePoint Pharmaceuticals, joins John and Scott to parse the LUGANO Phase 3 topline data — just three days after release. He walks through Duravyu's MOA, what the nine outlier patients in the study actually represent, why the secondary data are compelling, and what LUCIA needs to show for an NDA filing in 1H 2027.
Then Miles Harper stops by the VitreoRetinal View to discuss why some innovations in the OR fail, why others succeed, and which surgical applications of AI might feasibly appear in the near future.
Show Notes:
Guest: Jay S. Duker, MD – President & CEO, Board Director, EyePoint Pharmaceuticals; former Professor & Chair, Department of Ophthalmology, Tufts Medical Center and Tufts University School of Medicine
Show Summary
Three days after EyePoint Pharmaceuticals released topline LUGANO Phase 3 data, Jay S. Duker, MD, President & CEO, joins John Kitchens, MD, and Scott Krzywonos to break down what the results actually mean.
Duravyu (vorolanib) missed its primary non-inferiority endpoint in the full dataset of LUGANO — confounded by nine patients in the treatment arm who lost 15 or more letters for reasons unrelated to wet AMD control. Dr. Duker explains what those nine cases represent, why the secondary data tell a different story, and what LUCIA — the companion Phase 3 trial with topline data expected in Q4 2026 — will need to show for an NDA submission in 1H 2027.
John and Scott offer their own read on the interview: what surprised them, why the re-randomization analysis matters, and why TKIs are still likely to have a meaningful role in retina.
In the Vitreoretinal View segment, industry consultant and friend of the pod Miles Harper stops by to examine why some surgical innovations fail while others experience modest success. Scott and Miles also speculate as to which surgical applications of AI technology could soon enter the stage.
Hosts: John Kitchens, MD, Scott Krzywonos
Topics Covered
Duravyu: Mechanism & Background
Vorolanib is a small-molecule TKI with activity against all VEGF receptors — working intracellularly at the receptor level, unlike approved anti-VEGFs that block the ligand extracellularly. Additional activity against PDGF (antifibrotic) and JAK1 (anti-inflammatory via IL-6 pathway). Delivered via Durasert E bioerodible sustained-release insert; 2.7 mg every six months.
Previously tested orally in wet AMD with efficacy but hepatotoxicity at 200–300 mg daily; intravitreal dose results in only picogram-level systemic absorption. Tested in DAVIO (Phase 1), DAVIO 2 (Phase 2 wet AMD, 100% previously treated), and VERONA (Phase 2 DME) before Phase 3.
LUGANO Results: The Good
Safety: no increase in cataracts or IOP; single case of intraocular inflammation (0.5%); only 6% discontinuation rate in each arm, none due to study drug; safety confirmed with re-injection at month eight — the first TKI Phase 3 trial to read out with re-injection data.
Anatomic control: 4-µm difference in retinal thickness vs. aflibercept 2 mg at week 56. Supplement-free subgroup (~54% of Duravyu eyes at week 56) was non-inferior to the control arm with only a 3-µm OCT difference.
Treatment burden: 42% reduction vs. on-label aflibercept; approximately two fewer injections per year. At week 32, 76% of Duravyu patients were supplement-free.
Previously treated population: 25% of patients were previously treated — the first wet AMD Phase 3 trial to include this population; informed by DAVIO 2, which enrolled 100% previously treated patients and produced strong results.
LUGANO Results: The Primary Endpoint Miss
Control arm outlier performance: historically, ~4% of aflibercept 2 mg patients lose 15+ letters in Phase 3 wet AMD trials; in LUGANO, only 0.5% did — an extraordinary result that raises questions about randomization luck rather than drug performance.
The nine outlier patients: six lost vision due to GA progression, two due to glaucoma, one due to retinal detachment (repaired, but phakic — developed cataract). EyePoint's position: these losses were not related to Duravyu or lack of wet AMD control; GA data from the trial does not support drug-induced acceleration.
Re-randomization analysis: EyePoint randomly redistributed the 15+ letter losers across both arms ten times; in every simulation, Duravyu was non-inferior, with a mean difference of -1.3 to -2.0 letters — well within the non-inferiority margin.
Regulatory Path Forward
LUCIA topline data expected Q4 2026; if positive, NDA submission planned for 1H 2027. Precedents for one positive and one missed Phase 3: pegcetacoplan (DERBY/OAKS) and Lytenava. Dr. Duker: the FDA evaluates totality of data including safety, burden reduction, and clinical benefit — a positive LUCIA plus the LUGANO secondary data could constitute a compelling package.
Key Takeaways
Duravyu's LUGANO miss appears to be driven by statistical bad luck — nine patients, unrelated to wet AMD, in one arm — not a drug failure. The secondary data are strong.
The re-randomization analysis gives meaningful confidence that regression to the mean in LUCIA should produce a non-inferior result.
A positive LUCIA trial, combined with LUGANO's secondary data, may be sufficient for FDA approval — precedent exists for one missed and one positive Phase 3.
TKIs work as a class: treatment-free interval data from LUGANO are consistent with SOL-1, regardless of primary endpoint outcome.
Credits
Production & Marketing: Laura Brown | Business Operations: Liz Hogan
🎧 Listen at RetinUp.com | Apple Podcasts | Spotify | YouTube
Breaking News: EyePoint's Phase 3 Topline Data Release
2026/08/17
Breaking news: EyePoint Pharmaceuticals announced LUGANO Phase 3 topline data this morning. Duravyu, an investigational sustained-release TKI for wet AMD, did not meet its primary non-inferiority endpoint in the full dataset — confounded by nine patients in what EyePoint is calling an asymmetric cohort. John Kitchens, MD, and Scott Krzywonos break down what it means, what comes next, and why TKIs still win as a class.
Show Summary
Breaking news: EyePoint Pharmaceuticals announced topline data from LUGANO, the first of two pivotal Phase 3 trials evaluating Duravyu (vorolanib) for wet AMD, on the morning of August 17, 2026.
The primary non-inferiority endpoint was not met in the full dataset. EyePoint attributes this to an asymmetric cohort of nine patients in the treatment arm whose outcomes significantly skewed the results. In an unplanned ad hoc analysis excluding those nine patients, Duravyu was non-inferior to aflibercept 2 mg. Safety was clean, treatment-free intervals were compelling, and the companion LUCIA study remains on track for Q4 2026 topline data.
John Kitchens, MD, and Scott Krzywonos recorded this episode before the market opened to break down the study design, the ad hoc analysis question, and what the FDA is likely to do with these data. Plus, they examine why TKIs as a class — and some other companies — may be the real winners from this morning's news.
Hosts: John Kitchens, MD, Scott Krzywonos
Topics Covered
LUGANO Topline Data: What Happened
Study design: randomized, double-masked, non-inferiority trial; Duravyu 2.7 mg every six months vs. aflibercept 2 mg every other month (EOM); 211 patients in the treatment arm; a significant percentage of patients were previously treated — an unusual and real-world-reflective design feature; primary endpoint assessed at weeks 52 and 56.
Primary endpoint: not met in the full dataset; control arm performed exceptionally well — no patients lost three or more lines of vision in the first six months, compared to approximately 5% in historical wet AMD Phase 3 comparators.
The asymmetric cohort: nine patients in the treatment arm drove the primary endpoint miss; EyePoint characterizes these as an atypical subgroup. In an unplanned ad hoc analysis excluding these nine patients, Duravyu was non-inferior to the control arm.
Ad hoc analysis: not a pre-specified endpoint; FDA may consider it but likely will not base approval on it alone. The key question is whether LUCIA — the companion trial — delivers a clean positive result. John's view: LUCIA will need to be positive for any approval pathway; the FDA has approved products on one pivotal trial before (e.g., pegcetacoplan in DERBY/OAKS), so a strong LUCIA result may be sufficient.
Treatment-free intervals: approximately 42% reduction in treatment burden vs. aflibercept; roughly consistent with data from SOL-1 — validating the TKI mechanism as durable. At week 32, 76% of Duravyu patients were supplement free.
Safety: clean; no ocular inflammation, vasculitis, or unexpected safety signals; consistent with prior TKI studies and anti-VEGF experience.
What It Means for the Field
TKIs win as a class: treatment-free interval data confirm durability and mechanism; the question is not whether TKIs work but how they will be positioned alongside next-generation anti-VEGFs.
Second-generation anti-VEGFs as potential beneficiaries: aflibercept 8 mg and faricimab approximate extended intervals with approved labeling; a delayed or complicated TKI approval pathway could strengthen their near-term positioning.
Study design implications: John raises the question of whether future TKI trials will exclude patients with geographic atrophy or other confounders; enrollment criteria may tighten, potentially slowing trial timelines.
AI and enrollment: Scott raises the possibility that AI-assisted health record analysis could better identify appropriate candidates in real time — particularly relevant as trials increasingly enroll previously treated patients.
What's Next
LUCIA topline data: expected Q4 2026; if positive, EyePoint plans NDA submission in 1H 2027.
Upcoming RetinUp episode: John and Scott plan to speak with someone from EyePoint Pharmaceuticals to go deeper on the data; additional subgroup analyses will be presented at the Retina Society Annual Meeting, September 23–26, 2026.
Key Takeaways
LUGANO missed its primary endpoint, but EyePoint argues the result was driven by nine atypical patients — not a failure of the drug.
The ad hoc analysis showing non-inferiority is hypothesis-generating, not approval-enabling; LUCIA must be positive for an NDA to proceed.
TKIs work: treatment-free interval data from LUGANO are consistent with SOL-1, reinforcing the class mechanism.
All eyes are on LUCIA in Q4 2026.
Credits
Production & Marketing: Laura Brown | Business Operations: Liz Hogan
🎧 Listen at RetinUp.com | Apple Podcasts | Spotify | YouTube
Oncology's Biosimilar Lessons for Retina | Plus, Moving to a New OR
2026/08/13
The companion piece to RetinUp’s previous episode on biosimilars is here, featuring an oncologist who has lived through biosimilar disruption for the past decade. Stephen "Fred" Divers, MD, CMO of the American Oncology Network, joins John and Scott to share what oncology has learned from nearly a decade of biosimilar use: the ASP deterioration cycle, payer formulary pressure, the race to the bottom, and what retina should do differently as its own biosimilar era accelerates.
During the Vitreoretinal View segment, John discusses his fresh move to Boulder, sharing what it's like to operate in a new OR for the first time in years — new staff, new preferences to rebuild, and a new clinical reality: operating at 5,400 feet above sea level requires adjusting gas concentrations, counseling patients about altitude travel, and understanding why the vacuum on a vitrectomy machine behaves differently.
Hosts: John Kitchens, MD, Scott Krzywonos
Topics Covered
Biosimilars in Oncology: Lessons for Retina (Stephen "Fred" Divers, MD)
History: biosimilars entered the EU in 2005, the US in 2008 under the 351(k) pathway; oncology has roughly a decade of meaningful real-world experience.
The ASP deterioration cycle: when biosimilars enter the market, manufacturers offer rebates to drive prescribing behavior; those rebates fold into ASP prospectively at roughly six months, causing progressive price deflation. With each additional market entrant, competition intensifies and the race to the bottom accelerates.
The life cycle: the first biosimilar offers meaningful margin; by the second or third entrant, margins erode significantly. Manufacturers may pull products, let ASP reset, then reinsert. Ironically, the originator drug can eventually offer the best margin — after cycling through multiple biosimilars.
Payer formulary mandates: when payers limit formulary to a single biosimilar, practices can become underwater if that product takes a price increase before ASP catches up. Dr. Divers' approach: push back on single-product mandates and discourage manufacturers from taking price increases after securing guaranteed market share.
Formulary management: keep less than 48 hours of drug on hand; constantly renegotiate contracts as new biosimilars enter; treat formulary decisions as a quarterly exercise, not an annual one.
Patient experience: biosimilar transitions are largely invisible to patients from an efficacy and safety standpoint; batch-to-batch variability exists even within originator biologics, which is part of the scientific rationale for the biosimilar framework.
340B context: a program originally designed for underserved clinics treating HIV patients that expanded exponentially into hospital systems, now accounting for 50–60% of drug dispensing nationally. Creates perverse incentives that complicate biosimilar adoption decisions in oncology.
What retina should do differently: build operational flexibility for frequent formulary changes; don't set and forget; invest in pharmacy infrastructure; expect continuous renegotiation; and be prepared for the margin on any given biosimilar to disappear faster than anticipated.
Vitreoretinal View: Operating in a New OR — and at Altitude
John has joined Rocky Mountain Retina Associates in Boulder, Colorado, alongside Geeta Lalwani, MD.
New OR realities: starting fresh means rebuilding every case card preference — forceps, drape, glove size, block needle, prep protocol, etc. An email requesting a case card was the prompt that made John realize how much institutional knowledge travels with a surgeon invisibly.
First days: stick with the familiar; introduce changes only once settled. Forceps especially — "like tennis shoes, you don't change brands that often." Alcon and Zeiss reps were on-site to support the transition.
Operating at altitude (5,400 feet): SF6 gas concentration must be reduced compared to sea level use; John typically uses 28–30% SF6 at Lexington's elevation; this must be adjusted in Boulder. Patients must be counseled against travel above 7,000–9,000 feet until the bubble resolves — patients who live at altitude must plan accordingly.
Vacuum performance: the Alcon Constellation cannot achieve the same vacuum at 5,400 feet as at sea level; surgeons operating at altitude should be aware of this mechanical limitation and adjust technique accordingly.
Key Takeaways
Biosimilar margins are meaningful early and deteriorate fast — retina specialists should plan for continuous formulary management, not annual decisions.
Payer formulary mandates to a single biosimilar are the highest-risk scenario; practices should push back and keep options open.
Biosimilars are clinically safe and effective; the challenge is entirely economic and operational, not clinical.
Operating in a new OR requires rebuilding institutional knowledge from scratch — and at altitude, requires recalibrating both gas concentrations and patient counseling.
Sponsors
RetinUp is an editorially independent podcast supported with advertising.
This episode is made possible by Genentech, maker of Vabysmo (faricimab-svoa). Watch their Purple Chair Series at Vabysmo-hcp.com.
Learn more about Alcon’s Unity VCS at UnityVCS.com.
Credits
Production & Marketing: Laura Brown | Business Operations: Liz Hogan
🎧 Listen at RetinUp.com | Apple Podcasts | Spotify | YouTube
Podcast sponsorship advertising
Start advertising on RetinUp Podcast relevant audience podcasts
You may also like to advertise on these Podcasts

4.828116459
Huberman Lab
Scicomm Media

4.240683
To Be The Man
Podcast Heat | Cumulus Podcast Network

4.41511782000
The Ben Shapiro Show
The Daily Wire

4.2155648
TENNIS.com Podcast
TENNIS.com Podcast/Tennis Channel Podcast Network

4.510879779
The Joe Budden Podcast
The Joe Budden Network

4.611699506
The Bulwark Podcast
The Bulwark

4.711532393
Matt and Shane's Secret Podcast
Matt McCusker & Shane Gillis

4.72577183
Smosh Reads Reddit Stories
Smosh

4.975278756
Small Town Murder
James Pietragallo, Jimmie Whisman

4.71326596
Bulwark Takes
The Bulwark